China halts Sun Pharma rivastigmine sales
Change
On January 26, 2026, China's National Medical Products Administration ordered a halt to the import, sale, and use of Sun Pharmaceutical Industries' rivastigmine hydrogen tartrate capsules.
Why it matters
A remote inspection identified shortcomings in the company's production processes, including failures in contamination prevention and in the quality management department’s fulfillment of duties. The regulator's action covers rivastigmine hydrogen tartrate capsules and prohibits their importation, commercial sale, and clinical use within China. The ban was posted on January 26, 2026. Sun Pharmaceutical Industries did not provide a comment when contacted.
Implications
- • Importers and customs agents in China must stop bringing Sun Pharma's rivastigmine hydrogen tartrate capsules into the country.
- • Distributors, pharmacies, and hospitals in China must cease selling and supplying that specific rivastigmine formulation.
Unlock the decision layer.
Go beyond headlines — see impact, exposure, and timing.
- Implications: What actually changes downstream.
- Who is affected: Which teams or operators are exposed.
- What to watch: Deadlines, triggers, and next moves.
- Real-time alerts: Know the moment a change is published.
- Ask AI: Clarify any brief instantly, in context.
14-day free trial. Full access. No credit card required.
Start free trial
Source
Topics